Thrivent Financial for Lutherans’s C4 Therapeutics CCCC Stock Holding History

Thrivent Financial for Lutherans’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$247K	Buy	+52,763	New	+$180K	﹤0.01%	2507

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Thrivent Financial for Lutherans's CCCC Position: Q2 2026 in Review

Thrivent Financial for Lutherans opened a new position in C4 Therapeutics (CCCC) in Q2 2026: 52,763 shares worth $247K. The stake represents ﹤0.01% of the portfolio and ranks #2507 among its holdings.

148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Thrivent Financial for Lutherans held 52,763 shares of C4 Therapeutics worth $247K as of Q2 2026.
C4 Therapeutics was a new Thrivent Financial for Lutherans position in Q2 2026.
C4 Therapeutics made up ﹤0.01% of Thrivent Financial for Lutherans's portfolio in Q2 2026, its #2507 holding.
148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Thrivent Financial for Lutherans's 13F filing for Q2 2026, filed 14 Aug 2026.